RB Corporation – Life Changing Medicine Finance Analysis

Milka Cayoja, RB Martin, Abderahaman Sherif

BACKGROUND

  • Founded in 1995
  • The company´s focus is on providing a national center of expertise for regenerative medicine through developing and delivering therapies that reestablish tissue and function of organs impaired by disease, trauma, or congenital abnormalities.
  • Regenerative medicine is a new way of treating injuries and diseases that uses specially grown tissues and cells as well as laboratory made compounds.
  • Regenerative medicine is a new field that brings together experts in biology, chemistry, computer science, engineering, genetics, medicine, robotics, and other fields to find solutions to some of the most challenging medical problems faced by humankind.
Headquarters in San Francisco - California
CEO - RB Martin

Company Treatments

  • Cancer
  • Diabetes
  • Nervous System
  • Orthopedic
  • Respiratory assistance (Lungs)
  • Urinary Tract

Competitors

  • Cardeix Inc.- California, USA.
  • Immucor Inc. California, USA.
  • Thermo Fisher Scientific, California, USA.

·

Company Future Product

"Kidneys for life"

  • The National Kidney Foundation estimates that over 100,000 patient are on the waiting list for a donor kidney, and over 3000 are added to the list each year.
  • The average patient spends 3.6 years waiting for a viable transplant.

Product and project description

  • The project is creating a bio-hybrid device that can mimic a kidney by removing waste products, salt, and water, in the process keeping a patient off dialysis.
  • It is a silicon nanotechnology using living kidney cells to filter blood.
  • A series of 15 microchips serve as scaffolding for the living cells to grow on and around, creating a bio-hybrid device.

Production expected

The team announced that they were ready to begin pilot testing on their silicon filters, and they intend to launch the first human clinical trials for the artificial kidney technology in 2015. The results are successful so far, the treatment is going to be completed and ready to put on the market in 2018.

  • Will revolutionize the field of regenerative medicine.
  • Silicon Nanotechnology is going to be used on the project.
  • It is going to change the life of many people with kidney problems
  • Expected to procure lucrative DOD and business enterprise contracts

Problem

  • The loss of an important client, which represent a big percentage of the finances for research on the project.
  • The company has a minimal cash flow.
  • The new product and treatment is going to save the company however it requires two years to begin production:

- Patenting

- Tooling

- Final research and testing

Current Financial Analysis

Chart based on RB Corporation Annual report 2016
Chart based on RB Corporation Annual report 2016
Chart based on RB Corporation Annual report 2016
Chart based on RB Corporation Annual report 2016

SOLUTIONS

Raising capital to maintain current operation.

Introduce innovative product.

Finance options

Raising Capital

  • Government grant
  • Issuance of bonds
  • Issuance of common stock
  • Partnership
  • Tax carry back

Government Grant: Managed by the U.S. Department of Health and Human Services.

Partnership: Such as the National Institute of Biomedical.

Stocks and bonds

Tax carry back: From 2014 to 2015

CAPITAL STRUCTURE

Graphic based on RB Corporation Annual report 2016
Graphic based on RB Corporation Annual report 2016
Graphic based on RB Corporation Annual report 2016
Graphic based on RB Corporation Annual report 2016
Graphic based on RB Corporation Annual report 2016
Graphic based on RB Corporation Annual report 2016
Graphic based on RB Corporation Annual report 2016
Graphic based on RB Corporation Annual report 2016
Graphic based on RB Corporation Annual report 2016
Graphic based on RB Corporation Annual report 2016
Graphic based on RB Corporation Annual report 2016

Balance sheets

Chart based on RB Corporation Annual report 2016
Chart based on RB Corporation Annual report 2016
Chart based on RB Corporation Annual report 2016
Chart based on RB Corporation Annual report 2016

Conclusion

  • The financial situation of the corporation because of external factors requires securing financing for the short term.
  • The short term financing options are: Government grant, Issuance of common stock and Issuance bonds.
  • The company became successful because of the financial strategy implemented.

Biblical Integration

"Strategic planning is the key to warfare; to win you need a lot of good counsel" (Proverbs 24:6) MSG.

THANK YOU

Made with Adobe Slate

Make your words and images move.

Get Slate

Report Abuse

If you feel that this video content violates the Adobe Terms of Use, you may report this content by filling out this quick form.

To report a Copyright Violation, please follow Section 17 in the Terms of Use.